Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

Connect Biopharma (CNTB) announced that the Company’s collaborator and exclusive licensee in China, Simcere Pharmaceutical, has submitted its New ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in ...

New data reveals sponsors risk wasting billions by designing overly complex trials and repeatedly recruiting from oversaturated investigator sites Boston, US. 9 July, 2025. Dr. Gen Li, CEO of Phesi, a ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

July 8th, 2025 - Codex Labs, a biotech skincare company focused on microbiome-friendly solutions, is honored to participate ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...